Literature DB >> 3779115

Correlation of Fc gamma receptors on peripheral blood mononuclear cells and survival in patients with metastatic breast cancer.

D Ilfeld, J Barzilay, Z Dux, M Ran.   

Abstract

Patients with carcinomas have elevated levels of Fc receptors for IgG (Fc gamma R) on their peripheral blood mononuclear cells (PBMC). The purpose of the present study was to determine whether there is a correlation between Fc gamma R levels on PBMC and survival in patients with metastatic breast cancer. Binding assays were performed on PBMC using 125I-labeled fibrinogen complexed with rabbit IgG (or as a control F(ab')2) anti-human fibrinogen. Twenty-two metastatic breast cancer patients had significantly (p less than 0.001) elevated Fc gamma R levels as compared to either 22 breast cancer patients receiving adjuvant chemotherapy following mastectomy without clinical evidence of tumor, or to 34 non-malignant controls. Significantly more metastatic patients with elevated Fc gamma R levels died at 6 months (p less than 0.001) as compared to those with low levels. A direct correlation between Fc gamma R levels and hazard probability was found (correlation coefficient = 0.3321, p less than 0.005). These results raise the possibility that Fc gamma R levels on PBMC from metastatic breast cancer patients may be clinically useful as a prognostic marker of disease activity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3779115     DOI: 10.1007/bf01806248

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  11 in total

1.  Altered expression of human monocyte Fc receptors in malignant disease.

Authors:  J Rhodes
Journal:  Nature       Date:  1977-01-20       Impact factor: 49.962

2.  T lymphocytes with Fc-IgG receptors in skin cancers.

Authors:  G A Vena; G Angelini; R D'Ovidio; M Lospalluti; C L Meneghini
Journal:  Acta Derm Venereol       Date:  1981       Impact factor: 4.437

3.  Changes of blood T cell subsets following radiation therapy for breast cancer.

Authors:  B Petrini; J Wasserman; H Blomgren; U Glas
Journal:  Cancer Lett       Date:  1983-05       Impact factor: 8.679

4.  Quantitation of Fc receptor-bearing T-lymphocytes (TG and TM) in oral cancer.

Authors:  P Balaram; D M Vasudevan
Journal:  Cancer       Date:  1983-11-15       Impact factor: 6.860

5.  T-cell subpopulations in multiple myeloma: correlation with clinical disease status.

Authors:  M M Oken; N E Kay
Journal:  Br J Haematol       Date:  1981-12       Impact factor: 6.998

6.  Expression of Fc gamma receptors on a subpopulation of nonlymphoid tumor cells and its enrichment.

Authors:  M Ran; Z Dux; R Anavi; I P Witz
Journal:  J Natl Cancer Inst       Date:  1984-08       Impact factor: 13.506

7.  Prognostic factors in primary breast cancer.

Authors:  G M Clark; W L McGuire
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

8.  Fc receptor-bearing peripheral blood mononuclear cells in breast cancer patients: a possible marker of tumour burden and prognosis.

Authors:  J Bray; T A McPherson
Journal:  Clin Exp Immunol       Date:  1981-06       Impact factor: 4.330

9.  Subpopulations of human T-lymphocytes. XIX. T-cells and T-cells with receptors for IgMFc (T mu), IgGFc (T gamma), or IgAFc (T alpha) in the peripheral blood and regional lymph nodes of patients with untreated breast cancer.

Authors:  S Gupta; S Cunningham-Rundles
Journal:  J Natl Cancer Inst       Date:  1982-12       Impact factor: 13.506

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  1 in total

Review 1.  FcR may function as a progression factor of nonlymphoid tumors.

Authors:  I P Witz; M Ran
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.